Vortioxetine's post-marketing safety profile determined through cluster analysis of global adverse event reports

被引：0
|
作者：
Ekhart, Corine [1 ]
van Hunsel, Florence [1 ]
van Puijenbroek, Eugene [1 ,2 ]
Chandler, Rebecca [3 ]
Meldau, Eva-Lisa [3 ]
Noren, Niklas [3 ]
机构：
[1] Netherlands Pharmacovigilance Ctr Lareb, Shertogenbosch, Netherlands
[2] Univ Groningen, Groningen, Netherlands
[3] Uppsala Monitoring Ctr, Uppsala, Sweden
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
4070
引用
收藏
页码：497 / 497
页数：1
相关论文
共 50 条
  • [1] Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports
    Ekhart, Corine
    van Hunsel, Florence
    van Puijenbroek, Eugene
    Chandler, Rebecca
    Meldau, Eva-Lisa
    Taavola, Henric
    Noren, G. Niklas
    DRUG SAFETY, 2022, 45 (02) : 145 - 153
  • [2] Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports
    Corine Ekhart
    Florence van Hunsel
    Eugène van Puijenbroek
    Rebecca Chandler
    Eva-Lisa Meldau
    Henric Taavola
    G. Niklas Norén
    Drug Safety, 2022, 45 : 145 - 153
  • [3] SAFETY AND ADVERSE EVENT PROFILE OF TUMOR TREATING FIELDS IN ANAPLASTIC GLIOMA A POST-MARKETING SURVEILLANCE ANALYSIS
    Tran, David
    Kesari, Santosh
    Bota, Daniela A.
    NEURO-ONCOLOGY, 2018, 20 : 217 - 217
  • [4] Advancing drug safety science by integrating molecular knowledge with post-marketing adverse event reports
    Soldatos, Theodoros G.
    Kim, Sarah
    Schmidt, Stephan
    Lesko, Lawrence J.
    Jackson, David B.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (05): : 540 - 555
  • [5] TNF ANTAGONIST DRUG SAFETY ASSESSMENT BY PHARMACOVIGILANCE SIGNALING AND POST-MARKETING ADVERSE EVENT REPORTS
    Cavaco, M.
    Araujo, F.
    Eurico Fonseca, J.
    Goncalves, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 784 - 785
  • [6] Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
    Gastaldon, Chiara
    Raschi, Emanuel
    Kane, John M.
    Barbui, Corrado
    Schoretsanitis, Georgios
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2020, 90 (01) : 41 - 48
  • [7] Post-marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System
    Zhuang, Wei
    Xu, Jiabing
    Wu, Ye
    Yang, Jianhui
    Lin, Xiuxian
    Liao, Yufang
    Wan, Jun
    Weng, Lizhu
    Lin, Wanlong
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (09) : 2830 - 2842
  • [8] Post-marketing safety profile of ganirelix in women: a 20-year pharmacovigilance analysis of global adverse drug event databases (2004–2024)
    Yang Yang
    Zhiwei Cui
    Xiaoshan Feng
    Fan Zou
    Xiaoling Wu
    BMC Pharmacology and Toxicology, 26 (1)
  • [9] Post-marketing safety of finerenone: a disproportionality analysis of the FDA adverse event reporting system
    Jin, Yiyi
    Fan, Miao
    Zheng, Xiaomeng
    Zhu, Suyan
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [10] Safety of Bempedoic Acid: Post-marketing Analysis of the FDA Adverse Event Reporting System
    Raschi, E.
    Fusaroli, M.
    Forni, M.
    Goldman, A.
    Cicero, A. F. G.
    Poluzzi, E.
    Ponti, F. D.
    DRUG SAFETY, 2022, 45 (10) : 1287 - 1288
12345